

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Dated September 2, 2014

Commission File Number 001-36421

---

**AURINIA PHARMACEUTICALS INC.**

(Exact name of Registrant as specified in its charter)

---

N/A

(Translation of Registrant's Name)

#1203-4464 Markham Street  
Victoria, British Columbia  
V8Z7X8

(250) 708-4272

(Address and telephone number of registrant's principle executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

---

---

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 2, 2014

**Aurinia Pharmaceuticals Inc.**

By: /s/ Dennis Bourgeault

Name: Dennis Bourgeault

Title: Chief Financial Officer

---

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Description of Exhibit</u></b>
99.1	News Release - Aurinia Pharmaceuticals to begin trading on the NASDAQ Global Market

**NEWS RELEASE****Aurinia Pharmaceuticals to begin trading on the NASDAQ Global Market**

**VICTORIA, BRITISH COLUMBIA** – September 2<sup>nd</sup>, 2014 – Aurinia Pharmaceuticals Inc. (the “Company”) (TSX: AUP) today announced that the Company has received approval by the NASDAQ Listing Qualifications Department to list its common shares on the NASDAQ Global Market (“NASDAQ”). Trading will commence today, September 2<sup>nd</sup>, at the opening of the market under the trading symbol “AUPH”. The company’s shares will continue to trade on the Toronto Stock Exchange (“TSX”) under the trading symbol “AUP”.

“We are very pleased to have our common shares listed on both the TSX and the NASDAQ exchanges,” said Stephen Zaruby, President and Chief Executive Officer of the Company. “The listing on NASDAQ is a significant milestone for the Company and represents the culmination of a series of strategic restructuring steps undertaken by the Company. Management believes that by listing on NASDAQ, a premier U.S. stock exchange, the Company will increase awareness and provide greater liquidity for investors and institutions.”

***About Aurinia***

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Voclosporin is a novel and potentially best in class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,600 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.

Aurinia also has development and commercialization partners in Canada, Israel, South Africa and Greater China. Visit [www.auriniapharma.com](http://www.auriniapharma.com), [www.sedar.com](http://www.sedar.com) and [www.sec.gov](http://www.sec.gov) for more information.

**Company Contact:**

Stephen Zaruby  
President & Chief Executive Officer  
250-708-4293  
[szaruby@auriniapharma.com](mailto:szaruby@auriniapharma.com)

or

Michael R. Martin  
Chief Operating Officer  
250-708-4272  
[mmartin@auriniapharma.com](mailto:mmartin@auriniapharma.com)